Miricor Enterprises Holdings Ltd (1827) AI Stock Analysis

• Market Cap: HK$400.00M
• Dividend Yield: N/A
• Average Volume (3M): 21.33K
• Price to Earnings (P/E): 37.7
• Beta (1Y): -0.11
• Revenue Growth: -18.43%
• EPS Growth: N/A
• Country: HK
• Employees: 242
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Personal Products & Services
• EPS (TTM): 0.03
• Shares Outstanding: 400,000,000
• 10 Day Avg. Volume: 3,500
• 30 Day Avg. Volume: 21,333
• PEG Ratio: -0.24
• Price to Book (P/B): 3.17
• Price to Sales (P/S): 1.16
• P/FCF Ratio: 4.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$1.00
• Price Target Upside: 0.00%
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 59 Neutral
• Price Target: HK$1.00 ▲(0.00% Upside)

Miricor Enterprises Holdings Ltd demonstrates strong cash flow and improving profitability, which are significant strengths. However, the stock's bearish technical indicators and high valuation relative to earnings present challenges. The absence of dividend yield further impacts its attractiveness. Overall, the company shows resilience with potential for improvement, but current market conditions and valuation pose risks.

Miricor Enterprises Holdings Ltd Business Overview & Revenue Model

Company Description

Miricor Enterprises Holdings Limited, an investment holding company, provides medical aesthetic services in Hong Kong. It also offers a range of non-surgical medical aesthetic services, including energy-based and injection procedures. The company operates three medical aesthetic centers under the CosMax+ name. It also sells skin care products, such as cleansers, toners, serums, moisturizers, eye care products, ultraviolet protection products, and masks. Miricor Enterprises Holdings Limited was founded in 2009 and is headquartered in Causeway Bay, Hong Kong.

How the Company Makes Money

Miricor Enterprises Holdings Ltd generates revenue through multiple key streams, primarily from the sale of its biotechnology and healthcare products. The company earns income by commercializing its proprietary medical devices, which are marketed to hospitals, clinics, and healthcare providers. Additionally, Miricor benefits from research and development contracts, collaborating with other firms and institutions to innovate and enhance its product offerings. Significant partnerships with healthcare organizations and distributors play a crucial role in expanding its market reach and driving sales. Furthermore, the company may derive revenue from licensing agreements, allowing other entities to utilize its technology and inventions for a fee, thus diversifying its income sources.

Miricor Enterprises Holdings Ltd Financial Statement Overview

Summary

Miricor Enterprises Holdings Ltd shows strengths in cash flow generation and improving profitability margins. The reduction in leverage and improved return on equity are positive indicators of financial health. However, the decline in revenue growth poses a challenge, requiring strategic initiatives to drive sales.

Income Statement

Miricor Enterprises Holdings Ltd has shown a decline in revenue growth with a negative rate of -11.85% in the latest year, indicating a contraction in sales. However, the company has improved its gross profit margin to 52.37%, suggesting effective cost management. The net profit margin has turned positive at 2.63%, recovering from previous losses, which is a positive sign of profitability. The EBIT and EBITDA margins have also improved, reflecting better operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has decreased to 0.60, indicating a reduction in leverage and a more stable financial structure. Return on equity has improved to 7.18%, showing better utilization of shareholder funds. The equity ratio stands at 31.30%, suggesting a moderate level of equity financing relative to total assets, which provides a cushion against financial risks.

Cash Flow

Miricor Enterprises has achieved a strong free cash flow growth rate of 31.00%, demonstrating improved cash generation capabilities. The operating cash flow to net income ratio is 4.32, indicating robust cash flow relative to net income. The free cash flow to net income ratio is high at 98.29%, reflecting efficient conversion of earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	457.33M	403.15M	494.26M	463.12M	363.92M	128.87M
Gross Profit	234.83M	211.13M	225.37M	238.23M	209.54M	44.99M
EBITDA	48.77M	106.36M	86.62M	70.34M	94.02M	16.93M
Net Income	-196.00K	10.59M	-12.62M	-20.50M	25.38M	-12.65M
Balance Sheet
Total Assets	468.67M	471.28M	479.44M	516.81M	476.81M	372.13M
Cash, Cash Equivalents and Short-Term Investments	128.56M	192.17M	182.43M	179.32M	128.16M	161.77M
Total Debt	109.84M	88.76M	99.75M	130.28M	127.58M	42.49M
Total Liabilities	332.06M	323.72M	342.68M	366.10M	305.54M	226.56M
Stockholders Equity	136.61M	147.56M	136.76M	150.71M	171.27M	145.57M
Cash Flow
Free Cash Flow	85.55M	112.07M	58.24M	72.67M	-67.61M	19.07M
Operating Cash Flow	96.47M	114.02M	84.45M	99.45M	44.03M	24.54M
Investing Cash Flow	-28.22M	-30.95M	-59.00M	-37.84M	-97.51M	52.20M
Financing Cash Flow	-68.22M	-50.03M	-55.59M	-21.92M	-28.73M	-14.65M

Miricor Enterprises Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1827, the sentiment is Negative. The current price of 1 is below the 20-day moving average (MA) of 1.02, below the 50-day MA of 1.05, and below the 200-day MA of 1.11, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 37.65 is Neutral, neither overbought nor oversold. The STOCH value of 22.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1827.

Miricor Enterprises Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1161	74 Outperform	HK$626.11M	7.47	21.96%	5.98%	-1.62%	-10.07%
8603	72 Outperform	HK$1.77B	38.64	43.10%	―	45.40%	12.38%
1830	62 Neutral	HK$1.73B	8.44	54.45%	12.02%	-19.05%	-34.49%
1827	59 Neutral	HK$400.00M	37.74	7.45%	―	-18.43%	―
0919	46 Neutral	HK$69.65M	-13.75	-2.73%	―	-0.31%	47.17%
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%

Miricor Enterprises Holdings Ltd Corporate Events

Miricor Enterprises Announces 2025 AGM Agenda

Miricor Enterprises Holdings Ltd has announced its upcoming Annual General Meeting (AGM) to be held on September 23, 2025, in Hong Kong. Key agenda items include the consideration of audited financial statements, re-election of directors, re-appointment of auditors, and authorization for the board to manage share-related activities. These resolutions are aimed at ensuring continued corporate governance and operational efficiency.

Miricor Enterprises Reports Turnaround Despite Revenue Decline

Miricor Enterprises Holdings Ltd reported a significant decrease in revenue for the year ended March 31, 2025, amounting to approximately HK$403.2 million, an 18.4% drop from the previous year. Despite the revenue decline, the company achieved a turnaround, reporting a profit of approximately HK$10.6 million compared to a loss of HK$12.6 million the previous year, indicating improved financial performance.

Miricor Enterprises Holdings Ltd Strengthens Board Governance with New Nomination Committee Terms

Miricor Enterprises Holdings Ltd has outlined the terms of reference for its Nomination Committee, which is composed of three directors, primarily independent non-executive directors, and includes at least one member of a different gender. The committee is tasked with reviewing the board’s structure, size, and composition, identifying and recommending candidates for board membership, assessing the independence of non-executive directors, and implementing the company’s Board Diversity Policy. This initiative reflects the company’s commitment to maintaining a diverse and effective board, which is crucial for aligning with its corporate strategy and ensuring robust governance practices.